Adalimumab
Indication
Crohn's disease, 1st line biologic (NICE TA187) and LSCMMG Recommendation
NICE TA187 - Infliximab and adalimumab for the treatment of Crohn's Disease
Red
Brand:
Humira®
Nice TA:
187
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
Adalimumab is recommended as a treatment option for adults with severe active Crohn’s disease whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: